Matching articles for "Januvia"
Bexagliflozin (Brenzavvy) — A Fifth SGLT2 Inhibitor for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • August 21, 2023; (Issue 1683)
Bexagliflozin (Brenzavvy – TheracosBio), a sodium-glucose
cotransporter 2 (SGLT2) inhibitor, has been
approved by the FDA to improve glycemic control
in adults with type 2 diabetes. It is the fifth...
Bexagliflozin (Brenzavvy – TheracosBio), a sodium-glucose
cotransporter 2 (SGLT2) inhibitor, has been
approved by the FDA to improve glycemic control
in adults with type 2 diabetes. It is the fifth SGLT2
inhibitor to be approved in the US for this indication
(see Table 4).
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • November 14, 2022; (Issue 1663)
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
require antihyperglycemic drug therapy. Treating to
a target A1C of...
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
require antihyperglycemic drug therapy. Treating to
a target A1C of <7% while minimizing hypoglycemia
is recommended to prevent microvascular complications
of diabetes (retinopathy, nephropathy, and
neuropathy). An A1C target of <8% may be appropriate
for some older patients.
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • November 4, 2019; (Issue 1584)
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
eventually require drug therapy. Treating to a glycated
hemoglobin (A1C) concentration of...
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
eventually require drug therapy. Treating to a glycated
hemoglobin (A1C) concentration of <7% can prevent
microvascular complications (retinopathy, nephropathy,
and neuropathy), but whether it prevents macrovascular
complications and death is unclear. An A1C target of
<8% may be appropriate for older patients and those
with underlying cardiovascular disease (CVD), a history
of severe hypoglycemia, diabetes-related complications,
a limited life expectancy, or a long duration of disease.
Cardiovascular Effects of Some Antidiabetic Drugs
The Medical Letter on Drugs and Therapeutics • August 14, 2017; (Issue 1527)
For many years, the goal of drug therapy for most
patients with type 2 diabetes has been to achieve
and maintain an A1C of...
For many years, the goal of drug therapy for most
patients with type 2 diabetes has been to achieve
and maintain an A1C of <7%. Achieving that goal
can prevent microvascular complications (diabetic
retinopathy, nephropathy, neuropathy), but whether it
prevents macrovascular complications (myocardial
infarction [MI], stroke) has been less clear. The FDA
now requires that cardiovascular safety studies be
performed for all new drugs for type 2 diabetes.1
Recent findings that some of the newer second-line
drugs for type 2 diabetes have cardiovascular benefits
have led to new interest in the cardiovascular efficacy
and safety of all antidiabetic drugs.
Prescription Drug Prices in the US
The Medical Letter on Drugs and Therapeutics • May 22, 2017; (Issue 1521)
Per capita spending on prescription drugs in the US is
higher than in other industrialized nations,...
Per capita spending on prescription drugs in the US is
higher than in other industrialized nations, including
Canada.
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • January 16, 2017; (Issue 1512)
The goal of drug therapy for type 2 diabetes is
to achieve and maintain a near-normal glycated
hemoglobin (A1C) concentration without inducing
hypoglycemia; the target is generally an A1C of
≤7%. Treating...
The goal of drug therapy for type 2 diabetes is
to achieve and maintain a near-normal glycated
hemoglobin (A1C) concentration without inducing
hypoglycemia; the target is generally an A1C of
≤7%. Treating to this target has been shown to
prevent microvascular complications (retinopathy,
nephropathy, and neuropathy), but whether it prevents
macrovascular outcomes is unclear. An A1C target of
<8% may be appropriate for older patients and those
with underlying cardiovascular disease, a history of
severe hypoglycemia, diabetes-related complications
or comorbidities, or a long duration of disease.
Jentadueto XR for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • August 1, 2016; (Issue 1500)
The FDA has approved Jentadueto XR (Boehringer
Ingelheim/Lilly), a once-daily extended-release formulation
of the dipeptidyl peptidase-4 (DPP-4) inhibitor
linagliptin and the biguanide metformin, for...
The FDA has approved Jentadueto XR (Boehringer
Ingelheim/Lilly), a once-daily extended-release formulation
of the dipeptidyl peptidase-4 (DPP-4) inhibitor
linagliptin and the biguanide metformin, for oral
treatment of type 2 diabetes. Linagliptin and metformin
have been available for years in a twice-daily immediate-release combination (Jentadueto). Once-daily
extended-release formulations combining metformin
with the DPP-4 inhibitors saxagliptin (Kombiglyze XR)
and sitagliptin (Janumet XR) are also available.
Glyxambi - A New Combination for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • April 27, 2015; (Issue 1467)
The FDA has approved Glyxambi (Boehringer
Ingelheim/Lilly), a fixed-dose combination of empagliflozin
(Jardiance) and linagliptin (Tradjenta), for oral
treatment of type 2 diabetes in adults. It is the...
The FDA has approved Glyxambi (Boehringer
Ingelheim/Lilly), a fixed-dose combination of empagliflozin
(Jardiance) and linagliptin (Tradjenta), for oral
treatment of type 2 diabetes in adults. It is the first
combination of a sodium-glucose co-transporter 2
(SGLT2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor to be approved in the US.
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • March 1, 2014; (Issue 139)
The goal of drug therapy for type 2 diabetes is to achieve and
maintain a near-normal A1C concentration without
inducing hypoglycemia; the target is generally an A1C
of 10,000 patients with type 2...
The goal of drug therapy for type 2 diabetes is to achieve and
maintain a near-normal A1C concentration without
inducing hypoglycemia; the target is generally an A1C
of <7.0%. Treating to this target has been shown to
prevent the microvascular complications of retinopathy
and nephropathy, but whether it prevents macrovascular
outcomes remains unclear. Three large trials found
that intensive glucose control did not reduce the
incidence of macrovascular events. One of these trials
(ACCORD) in >10,000 patients with type 2 diabetes,
with or at high-risk for cardiovascular disease, found
that treating patients intensively with antihyperglycemic
drugs to an A1C target of 6.0% for a mean of 3.7 years
did not significantly reduce the incidence of major
cardiovascular events (the primary endpoint) and was
associated with increased all-cause mortality compared
to patients treated to an A1C target of 7.0-7.9%. An
A1C target of 7-8% may be prudent in older patients
and in those with underlying cardiovascular disease,
severe hypoglycemia, or multiple diabetes-related
complications or co-morbidities.
Alogliptin (Nesina) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • May 27, 2013; (Issue 1417)
The FDA has approved the dipeptidyl peptidase-4
(DPP-4) inhibitor alogliptin (Nesina – Takeda) for treatment
of type 2 diabetes. In addition to the single-ingredient
product, the FDA also approved...
The FDA has approved the dipeptidyl peptidase-4
(DPP-4) inhibitor alogliptin (Nesina – Takeda) for treatment
of type 2 diabetes. In addition to the single-ingredient
product, the FDA also approved fixed-dose
combinations of alogliptin/metformin (Kazano) and
alogliptin/pioglitazone (Oseni) for the same indication.
Alogliptin is the fourth DPP-4 inhibitor to become available
in the US. The other three – saxagliptin (Onglyza),
sitagliptin (Januvia), and linagliptin (Tradjenta) – are also
available in fixed-dose combinations with metformin.
Canagliflozin (Invokana) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • May 13, 2013; (Issue 1416)
Canagliflozin (kan" a gli floe' zin; Invokana – Janssen),
a sodium-glucose co-transporter 2 (SGLT2) inhibitor,
has been approved by the FDA for oral treatment of
type 2...
Canagliflozin (kan" a gli floe' zin; Invokana – Janssen),
a sodium-glucose co-transporter 2 (SGLT2) inhibitor,
has been approved by the FDA for oral treatment of
type 2 diabetes.
What Comes After Metformin for Type 2 Diabetes?
The Medical Letter on Drugs and Therapeutics • July 23, 2012; (Issue 1395)
Most experts agree that lifestyle modifications and
metformin (Glucophage, and others) should be used
first to treat patients with type 2 diabetes. If metformin
alone fails to control hyperglycemia, there...
Most experts agree that lifestyle modifications and
metformin (Glucophage, and others) should be used
first to treat patients with type 2 diabetes. If metformin
alone fails to control hyperglycemia, there is
no general agreement on which drug should be
added next. A recent article in The Medical Letter
offered some support for a sulfonylurea. Three
recent trials published in The Lancet favored the
long-acting basal insulin glargine, the glucagon-like
peptide (GLP-1) analog exenatide, and the dipeptidyl
peptidase-4 (DPP-4) inhibitor linagliptin, respectively.
Some of the advantages and disadvantages of
these and other available agents are listed in Table 1
on the opposite page.
Linagliptin/Metformin (Jentadueto) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • May 14, 2012; (Issue 1390)
Linagliptin (Tradjenta) and metformin (Glucophage,
and others) are now available as a fixed-dose combination
(Jentadueto – Boehringer Ingelheim/Lilly) for
oral treatment of type 2 diabetes in adults....
Linagliptin (Tradjenta) and metformin (Glucophage,
and others) are now available as a fixed-dose combination
(Jentadueto – Boehringer Ingelheim/Lilly) for
oral treatment of type 2 diabetes in adults. Metformin
is generally the preferred first-line agent for treatment
of type 2 diabetes, but most patients eventually
require treatment with multiple drugs. Linagliptin is
a dipeptidyl peptidase-4 (DDP-4) inhibitor like
sitagliptin (Januvia) and saxagliptin (Onglyza). Both
sitagliptin and saxagliptin are also available in fixed-dose
combinations with metformin.
Sitagliptin and Simvastatin (Juvisync)
The Medical Letter on Drugs and Therapeutics • November 14, 2011; (Issue 1377)
The FDA has approved Juvisync (Merck), a fixed-dose
combination of the antihyperglycemic DPP-4 inhibitor
sitagliptin (Januvia) and the HMG-CoA reductase
inhibitor simvastatin (Zocor, and...
The FDA has approved Juvisync (Merck), a fixed-dose
combination of the antihyperglycemic DPP-4 inhibitor
sitagliptin (Januvia) and the HMG-CoA reductase
inhibitor simvastatin (Zocor, and others).
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • August 1, 2011; (Issue 108)
The development of hyperglycemia in type 2 diabetes
results from a combination of metabolic abnormalities
that includes insulin resistance, diminished
insulin secretion and excess hepatic glucose...
The development of hyperglycemia in type 2 diabetes
results from a combination of metabolic abnormalities
that includes insulin resistance, diminished
insulin secretion and excess hepatic glucose production.
Diet, exercise and weight loss are helpful in
improving glucose control, but most patients ultimately
require drug therapy.
Linagliptin (Tradjenta) - A New DPP-4 Inhibitor for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • June 27, 2011; (Issue 1367)
Linagliptin (Tradjenta – Boehringer Ingelheim/Lilly), a
third oral dipeptidyl peptidase-4 (DPP-4) enzyme
inhibitor, was recently approved by the FDA for treatment
of type 2 diabetes, either alone or in...
Linagliptin (Tradjenta – Boehringer Ingelheim/Lilly), a
third oral dipeptidyl peptidase-4 (DPP-4) enzyme
inhibitor, was recently approved by the FDA for treatment
of type 2 diabetes, either alone or in combination
with metformin, a sulfonylurea or pioglitazone
Saxagliptin/Metformin (Kombiglyze XR) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • March 21, 2011; (Issue 1360)
Metformin (Glucophage, and others) is generally preferred as the first-line agent for treatment of type 2 diabetes, but most patients subsequently require treatment with more than one drug. Many combination...
Metformin (Glucophage, and others) is generally preferred as the first-line agent for treatment of type 2 diabetes, but most patients subsequently require treatment with more than one drug. Many combination products have been marketed; the latest of these combines saxagliptin with extended-release (ER) metformin as
Kombiglyze XR.
Saxagliptin (Onglyza) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • November 2, 2009; (Issue 1324)
Saxagliptin (Onglyza - Bristol-Myers Squibb), the second oral dipeptidyl peptidase-4 (DPP-4) inhibitor to be marketed in the US, has been approved by the FDA for treatment of adults with type 2...
Saxagliptin (Onglyza - Bristol-Myers Squibb), the second oral dipeptidyl peptidase-4 (DPP-4) inhibitor to be marketed in the US, has been approved by the FDA for treatment of adults with type 2 diabetes.
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • July 1, 2008; (Issue 71)
The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, diminished insulin secretion and excess hepatic glucose production. Diet,...
The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, diminished insulin secretion and excess hepatic glucose production. Diet, exercise and weight loss are helpful in improving glucose control, but most patients ultimately require drug therapy.
Sitagliptin/Metformin (Janumet) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • June 4, 2007; (Issue 1262)
Sitagliptin (Januvia) and metformin (Glucophage, and others) are now available in a single tablet (Janumet - Merck) for treatment of type 2 diabetes. The combination is approved by the FDA for use in patients...
Sitagliptin (Januvia) and metformin (Glucophage, and others) are now available in a single tablet (Janumet - Merck) for treatment of type 2 diabetes. The combination is approved by the FDA for use in patients not adequately controlled by sitagliptin or meformin alone or in those already taking both drugs. Metformin is also available in combination with the thiazolidinediones pioglitazone and rosiglitazone and with the sulfonylureas glipizide and glyburide.
Sitagliptin (Januvia) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • January 1, 2007; (Issue 1251)
Sitagliptin phosphate (Januvia - Merck) is the first dipeptidyl-peptidase-4 (DPP-4) inhibitor to be marketed for treatment of type 2 diabetes. It has been approved by the FDA for oral use as monotherapy or in...
Sitagliptin phosphate (Januvia - Merck) is the first dipeptidyl-peptidase-4 (DPP-4) inhibitor to be marketed for treatment of type 2 diabetes. It has been approved by the FDA for oral use as monotherapy or in combination with metformin (Glucophage, and others), pioglitazone (Actos) or rosiglitazone (Avandia).